US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

0.8650

-0.0739-7.87%

Volume:402.36K

Turnover:359.50K

Market Cap:14.54M

PE:-1.70

High:0.9400

Open:0.9400

Low:0.8601

Close:0.9389

Loading ...

Overview Company News Filings

Mira Pharmaceuticals Inc - to Acquire Skny Pharmaceuticals - SEC Filing

THOMSON REUTERS

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

MIRA Makes Significant Acquisition and Boosts Capital

Zacks Small Cap Research

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief

MT Newswires Live

BRIEF-Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

ACCESS Newswire

Mira Pharmaceuticals Inc - Advancing Ketamir-2 Topical Treatment Development for Future Clinical Trials

THOMSON REUTERS

BRIEF-Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain

Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial

Mira Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

THOMSON REUTERS

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

ACCESS Newswire

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

MIRA Announces Approval of Important Testing

Zacks Small Cap Research

Rising High: Exclusive talk with pharmaceutical development company MIRA

What Is Pump.fun? Everything About the Token Creation Platform

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Simply Wall St.

Whale loses $500K on MIRA token as charity token trend gains ground

Crypto Whale Turns $81.3K into $13.36M Profit with MIRA and FARTCOIN Tokens: A 1030x Return

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MIRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.865,"timestamp":1745265600000,"preClose":0.9389,"halted":0,"volume":402363,"delay":0,"floatShares":11764337,"shares":16813654,"eps":-0.508455,"marketStatus":"Pre-Mkt","change":-0.0739,"latestTime":"04-22 07:25:56 EDT","open":0.94,"high":0.94,"low":0.8601,"amount":359499.9938634,"amplitude":0.0851,"askPrice":0.9044,"askSize":200,"bidPrice":0.8302,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.508455,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":0.865,"postHourTrading":{"tag":"盘后","latestPrice":0.8614,"preClose":0.865,"latestTime":"19:54 EDT","volume":7310,"amount":6342.732,"timestamp":1745279674439},"volumeRatio":0.040061530771100945},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":11764337,"roa":"-127.59%","roe":"-238.90%","lyrEps":-0.508455,"volumeRatio":0.040061530771100945,"shares":16813654,"dividePrice":0,"high":0.94,"amplitude":0.0851,"preClose":0.9389,"low":0.8601,"week52Low":0.51,"pbRate":"6.61","week52High":5.01,"institutionHeld":0,"latestPrice":0.865,"committee":-0.99005,"eps":-0.508455,"divideRate":0,"volume":402363,"delay":0,"ttmEps":-0.508455,"open":0.94,"prevYearClose":1.14,"prevWeekClose":0.9389,"prevMonthClose":0.98,"prevQuarterClose":0.98,"fiveDayClose":0.8649,"twentyDayClose":1.28,"sixtyDayClose":1.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521974487","title":"Mira Pharmaceuticals Inc - to Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2521974487","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521974487?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:32","pubTimestamp":1742815978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q71E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2521741957","title":"EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741957","media":"Benzinga","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741957?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:16","pubTimestamp":1742814980,"startTime":"0","endTime":"0","summary":"On Monday, MIRA Pharmaceuticals, Inc.  signed a binding letter of intent  to acquire SKNY Pharmaceuticals, Inc.The transaction includes a $5 million capital infusion of cash or equivalent consideration into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation.Also Read: EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain. Under the terms, MIRA will acquire SKNY through a stock exchange, whereby SKNY shareholders will receive shares of MIRA common stock at a valuation determined by an independent third-party firm.Additionally, SKNY will contribute $5 million in cash or assets to MIRA at closing. Upon completion, SKNY-1 and all related intellectual property assets will be fully integrated into MIRA.The acquisition of SKNY Pharmaceuticals strategically positions MIRA to enter two high-growth pharmaceutical markets with a differentiate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-signs-acquire-111620782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2522972777","title":"MIRA Makes Significant Acquisition and Boosts Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522972777","media":"Zacks Small Cap Research","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522972777?lang=en_us&edition=fundamental","pubTime":"2025-03-24 18:14","pubTimestamp":1742811240,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just announced the beginning of clinical trials, illustrating further important advancement in the approval process.Ketamir-2 took a major step forward earlier this year with the company announcing that it has received authorization from t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-makes-significant-acquisition-boosts-101400240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","PSYGF","MYCOF","BK4202","BETRF","GHRS","BK4007","MNMD","SEEL","FLHLF","MDXXF","OPTHF","DRUG","ENTBF","SNPX","SPRC","BK4547","QNTM","CYBN","SILO","ALID","BK4539","NUMIF","BK4168","KTTA","CMND","PHRRF","CMPS","PBM","RLMD","ATAI","BK4139","IXHL","MIRA","NRXP","RVVTF"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SEEL","MNMD","AGNPF","PBM","NRXP","MDXXF","CYBN","NUMIF","FLHLF","ALID","QNTM","CMND","ATAI","MYCOF","RLMD","BK4539","CMPS","RVVTF","BK4202","BETRF","PHRRF","BK4007","IXHL","SPRC","DRUG","BK4168","PSYGF","BK4547","OPTHF","GHRS","SNPX","ENVB","KTTA","SILO","MIRA","ENTBF"],"gpt_icon":0},{"id":"2519347858","title":"Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief","url":"https://stock-news.laohu8.com/highlight/detail?id=2519347858","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519347858?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:29","pubTimestamp":1741872554,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals  said Thursday it has expanded its pain management portfolio by developing topical formulation of Ketamir-2 to treat localized neuropathic and inflammatory pain.The topical treatment of Ketamir-2 is developed for \"slow release\" to directly target the pain site, while also reducing systemic exposure and side effects, the company said, adding that potential applications include neuropathic pain conditions, inflammatory pain conditions, and nerve compression & musculoskeletal pain.Mira said it is currently carrying out a phase 1 clinical study for the Ketamir-2 oral treatment for neuropathic pain.MIRA shares were 3% higher ahead of Thursday's opening bell.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2519835999","title":"BRIEF-Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835999","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835999?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:06","pubTimestamp":1741867590,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory painMarch 13  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ANNOUNCES SUCCESSFUL FORMULATION OF KETAMIR-2 TOPICAL TREATMENTMIRA PHARMACEUTICALS INC - ADVANCING KETAMIR-2 TOPICAL TREATMENT DEVELOPMENT FOR FUTURE CLINICAL TRIALSFurther company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0QJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2519839573","title":"MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839573","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839573?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:00","pubTimestamp":1741867200,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief.\"The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,\" stated Erez Aminov, Chairman and CEO of MIRA. \"By advancing two distinct formulations, we are positioning Ketamir-2 to address multiple pain conditions and broaden its potential applications. This strategic approach strengthens our presence in the pain management space and underscores our commitment to delivering innovative solu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-expands-ketamir-2-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2519336008","title":"Mira Pharmaceuticals Inc - Advancing Ketamir-2 Topical Treatment Development for Future Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2519336008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519336008?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:48","pubTimestamp":1741866488,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0QJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2516674166","title":"BRIEF-Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674166","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674166?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:14","pubTimestamp":1741097693,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic PainMarch 4  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS ANNOUNCES APPROVAL AND INITIATION OF PHASE 1 CLINICAL TRIAL FOR KETAMIR-2 IN NEUROPATHIC PAINSource text: [ID:n0001493152-25-008977]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2516715296","title":"Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516715296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516715296?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:31","pubTimestamp":1741095084,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced the approval and upcoming initiation of its Phase 1 clinical trial for Ketamir-2, the Company’s novel oral ke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-approval-initiation-of-phase-1-ketamir-2-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-approval-initiation-of-phase-1-ketamir-2-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2516675093","title":"Mira Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675093?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:08","pubTimestamp":1741093681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2516762236","title":"MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2516762236","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516762236?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. , a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and upcoming initiation of its Phase 1 clinical trial for Ketamir-2, the Company's novel oral ketamine analog in development for neuropathic pain, with subject recruitment scheduled to begin in Q1 2025.The study has received authorization from the Israeli Ministry of Health and the Institutional Review Board  and will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel. This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers.In addition to assessing the frequency and severity of adverse events  and serious adverse events , the study will closely evaluate ketamine-relat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2516789675","title":"EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2516789675","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516789675?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:45","pubTimestamp":1741092318,"startTime":"0","endTime":"0","summary":"On Tuesday, the Israeli Ministry of Health and the Institutional Review Board  approved MIRA Pharmaceuticals, Inc.'s  Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain.In December, MIRA Pharmaceuticals submitted an Investigational New Drug  application to the FDA to start human trials for Ketamir-2.MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.Also Read: EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain. Subject recruitment is scheduled to begin in the first quarter of 2025.The study will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel.The Phase 1, randomized, double-blind, placebo-controlled, single-center study evaluates the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-mira-pharmaceuticals-kick-starts-124518585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2517606488","title":"MIRA Announces Approval of Important Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517606488","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517606488?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:08","pubTimestamp":1741086480,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals  is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company also acquired the rights to Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ketamine that has shown indications of having fewer side effects, working more rapidly, and having the opportunity to impact millions of patients that have not responded to other, existing treatments. We have written about the exciting preclinical results for Ketamir-2, the company’s novel oral ketamine analog, and the company just announced the beginning of clinical trials, illustrating further important advancement in the approval process.We remain extremely positive on MIRA, and this announcement is yet further confirmation that company management is on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-announces-approval-important-testing-110800394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2504914905","title":"Rising High: Exclusive talk with pharmaceutical development company MIRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2504914905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504914905?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:15","pubTimestamp":1737044118,"startTime":"0","endTime":"0","summary":"In this edition of “Rising High,” The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA Pharmaceuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rising-high-exclusive-talk-with-pharmaceutical-development-company-mira?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rising-high-exclusive-talk-with-pharmaceutical-development-company-mira?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2503321810","title":"What Is Pump.fun? Everything About the Token Creation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2503321810","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503321810?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:21","pubTimestamp":1736752912,"startTime":"0","endTime":"0","summary":"While market-making, order-flow, and trading platforms like DEXs find their product market fit with institutional crypto investors, Pump.fun appeals to the average retail trader via meme coins. The platform has shifted the dynamics of speculative trading in crypto markets and, as a result, lowered the barrier to entry for many users. Here’s what you need to know about the meme coin launchpad in 2025.Pump.fun makes it easy for anyone to launch a meme coin on Solana, lowering technical and financial barriers.Its step-function bonding curve mechanism drives trading by adjusting token prices at discrete supply intervals.Despite anti-rug-pull measures, scams and volatility remain a concern.Pump.fun’s unfiltered, decentralized model can establish creative freedom but also invites controversial behavior.Pros and cons of Pump.funThe enigma of Pump.fun’s open-access modelFrequently asked questions. my ultimate goal is for pump dot fun to be the most fun place on the internetif I don't achieve t","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2024/09/bic_Generic_Memecoins_2-covers_neutral-850x478.jpg.optimal.jpg","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2024/09/bic_Generic_Memecoins_2-covers_neutral-850x478.jpg.optimal.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/learn/what-is-pump-fun/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4213","DEC","TON.USD.CC","APT.USD.CC","BK4585","BK4007","DBC","TON.USD.HKCC","BK4588","RNDR.USD.HKCC","MIRA","APT.USD.HKCC"],"gpt_icon":0},{"id":"2501144214","title":"Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2501144214","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501144214?lang=en_us&edition=fundamental","pubTime":"2025-01-05 21:16","pubTimestamp":1736083001,"startTime":"0","endTime":"0","summary":"So, the natural question for MIRA Pharmaceuticals  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since its cash burn is increasing , MIRA Pharmaceuticals shareholders should still be mindful of the possibility it will require more cash in the future. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-131641039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","MNQmain","SQQQ","MIRA","BK4112",".IXIC","QID","TSYW.SI","USJW.SI","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","BK4585","NVIW.SI","LU2210149790.SGD","BK4007","PSQ","QLD","TQQQ","LU2210150020.SGD","USAW.SI","IE00BGHQF748.EUR","NQmain"],"gpt_icon":1},{"id":"2494046388","title":"Whale loses $500K on MIRA token as charity token trend gains ground","url":"https://stock-news.laohu8.com/highlight/detail?id=2494046388","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494046388?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:54","pubTimestamp":1735307687,"startTime":"0","endTime":"0","summary":"A whale lost $500K on the MIRA token, which built up hype around being linked to rare disease research. The token was tied to Siqi Chen, co-founder of Serious Business and Runway, with no previous connections to crypto or memes.The MIRA token saw active trading after a big part of the supply was sent to Siqi Chen, co-founder of Serious Business and Runway. The initial hype around the token suggested the asset would be used to fund research into rare diseases. However, soon after the launch, MIRA went through extreme volatility.Recently, MIRA wiped as much as $500K from a whale trader, who poured more than $1.56M into the token. The buyer is still holding, though. Within hours, the value of the token holdings fell to $718,000, extending its downward trend. Despite the noble cause, once Chen sold his share and whales took profit, the token did not find support from anywhere else.Before whales realized profits, Chen held up to $18M worth of MIRA tokens. Initially, the share was worth $400","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676eb1a88a03c8196e11c888/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2494877454","title":"Crypto Whale Turns $81.3K into $13.36M Profit with MIRA and FARTCOIN Tokens: A 1030x Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2494877454","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494877454?lang=en_us&edition=fundamental","pubTime":"2024-12-27 17:31","pubTimestamp":1735291872,"startTime":"0","endTime":"0","summary":"A crypto whale has received widespread attention after earning a huge profit by accumulating massive amounts of Chains of War (MIRA) and Fartcoin (FARTCOIN) tokens. The whale swapped $69,100 for MIRA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/676e73df3b1253069be45e7a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4007","APT.USD.HKCC","MIRA","APT.USD.CC","RNDR.USD.HKCC","TON.USD.HKCC","TON.USD.CC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":63,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1741406400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-04-21","current":-2.010318,"percent":0.44665,"low":-15.501022,"twenty":-3.583579,"median":-1.885876,"eighty":-1.325723,"high":-0.648567,"avg":-3.336817,"sd":3.605458,"marketCap":15786339},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-21","current":-2.010318,"twenty":-3.583579,"median":-1.885876,"eighty":-1.325723,"marketCap":15786339}],"updateTime":1745319464766}}}